Psilocybin Microdose for Psychological and Existential Distress in Palliative Care (PSYCHED-PAL-RCT)
About 30-50% of patients with advanced illness experience depression, anxiety, or decreased sense of purpose and autonomy. Together, these are called psychological distress. Treatment options such as medication and therapy are available; however, they do not always work and can be time-consuming and expensive. (The sponsor's summary, shortened.)
Eligibility and contacts on ClinicalTrials.govThe registry record
- Status
- Recruiting
- Phase
- Phase 3
- Conditions
- Psychological Distress
- Intervention
- Psilocybin; Placebo
- Sponsor
- Bruyère Health Research Institute.
- Ages
- 18 Years and over
- Sex
- All
- Healthy volunteers
- No
- Enrolment
- 120 people (planned)
- Start
- 28 January 2026
- Primary completion
- August 2027
- Registry last updated
- 10 July 2026
Sites (7)
- William Osler Health System, Brampton, Ontario, Canada (not yet recruiting)
- Providence Care Hospital, Kingston, Ontario, Canada (recruiting)
- St. Joseph's Healthcare, London, Ontario, Canada (not yet recruiting)
- South Lake Regional Health Centre, Newmarket, Ontario, Canada (recruiting)
- Bruyere Health, Ottawa, Ontario, Canada (recruiting)
- The Ottawa Hospital, Ottawa, Ontario, Canada (not yet recruiting)
- McGill University Health Centre, Montreal, Quebec, Canada (not yet recruiting)
How joining a trial works
- Free to take part
- Trials generally cost participants nothing for the study drug and the study visits, and some pay for travel or time. Check what a study covers on its registry page.
- Screened first
- Every study screens volunteers with questionnaires, medical history and often a physical and psychiatric check. Many people who apply are not enrolled.
- Eligibility is strict
- Common exclusions include a personal or family history of psychosis or bipolar disorder, some heart conditions, pregnancy and certain medications, which you may be asked to stop under medical supervision. Never stop a medication on your own to qualify.
- You may get a placebo
- Many trials compare psilocybin with a placebo or a low dose, and you may not be told which you had until the study ends.
- Contact the study team through the registry
- Each registry record lists the study contacts and sites. We do not republish personal emails or phone numbers; use the link on each trial page.
- Not medical advice
- This is a list of registry records, not a recommendation. Talk to your doctor before applying. Disclaimer · Safety and medications
Source: ClinicalTrials.gov API v2, U.S. National Library of Medicine, read 28 October 2026. Filter: overall status RECRUITING or NOT_YET_RECRUITING; an intervention named psilocybin, psilocin, COMP360 or CYB003. Refreshed weekly; a study's own registry page is always the current record.
Record read from ClinicalTrials.gov API v2, U.S. National Library of Medicine on 28 October 2026. All psilocybin trials